Osteodoron AM Bone Support
- Manufacturer
- Uriel Pharmacy Inc
- Effective date
- 2010-03-12
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-01 02:02:13
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
Purpose
Uses: For healthy teeth and bone development.
Dosage & Administration
Directions: Take in the morning. Use with Osteodoron PM Bone Support Powder. Ages 12 and older: 1/8 tsp. Ages 2-11: 1/16 tsp. Under
age 2: Ask a doctor.
OTC-Active Ingredient
Active Ingredients: Cucurbita e flor. 3X HPUS, Apatite 6X HPUS, Fluorite 6X HPUS, Quartz 6X HPUS.
Inactive Ingredient
Inactive Ingredient: Lactose
Keep out of reach of children
KEEP OUT OF REACH OF CHILDREN.
Do not use section
Warnings:
Do not use if allergic to any ingredient. Do not use if safety seal is broken or missing.
Ask doctor section
Consult your doctor if you are lactose intolerant, or if inadequate dietary calcium is a concern. When using this product, consult your doctor regularly to ensure that improvement is proceeding normally.
Pregnancy or breast feeding section
If you are pregnant or nursing, consult a doctor before use.
Questions section
Principal Display Panel
Osteodoron AM
Bone Support Powder
Homeopathic
net vol. 60 ml (2 fl. oz.)
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 48951-7096-4 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-5afd-f424-e053-dadaa90a57ce | Osteodoron AM Bone Support Powder - 60 ml |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 48951-7096-4 | Osteodoron AM Bone Support | 1 in 1 BOTTLE, GLASS | POWDER | 1 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 48951-7096 | OSTEODORON AM BONE SUPPORT (PUMPKIN SILICON DIOXIDE CALCIUM FLUORIDE FLUORAPATITE) POWDER [URIEL PHARMACY INC] | 1 | Legacy NDC, 1 package rows | 20100312_1dfca5e0-2bc6-11df-8a39-0800200c9a66.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CALCIUM FLUORIDE | ACTIVE INGREDIENT | O3B55K4YKI | 1 | |
| FLUORAPATITE | ACTIVE INGREDIENT | M4CM1H238J | 1 | |
| PUMPKIN | ACTIVE INGREDIENT | SYW0QUB89Y | 1 | |
| SILICON DIOXIDE | ACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| CALCIUM FLUORIDE | ACTIVE MOIETY | O3B55K4YKI | 1 | |
| FLUORAPATITE | ACTIVE MOIETY | M4CM1H238J | 1 | |
| PUMPKIN | ACTIVE MOIETY | SYW0QUB89Y | 1 | |
| SILICON DIOXIDE | ACTIVE MOIETY | ETJ7Z6XBU4 | 1 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 1 |
Products#
Every source-derived product name is available through these pages.
- Osteodoron AM Bone Support
- PUMPKIN SILICON DIOXIDE CALCIUM FLUORIDE FLUORAPATITE
- PUMPKIN
- SILICON DIOXIDE
- CALCIUM FLUORIDE
- LACTOSE
- FLUORAPATITE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 48951-7096 | 48951-7096-4 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| PUMPKIN | SYW0QUB89Y | ACTIB |
| SILICON DIOXIDE | ETJ7Z6XBU4 | ACTIB |
| CALCIUM FLUORIDE | O3B55K4YKI | ACTIB |
| LACTOSE | J2B2A4N98G | IACT |
| FLUORAPATITE | M4CM1H238J | ACTIB |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 009d1de0-2bc6-11df-8a39-0800200c9a66 | 1dfca5e0-2bc6-11df-8a39-0800200c9a66 | 2010-03-12 | 009d1de0-2bc6-11df-8a39-0800200c9a66 1dfca5e0-2bc6-11df-8a39-0800200c9a66 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
